Abingdon Health is pleased to announce a significant expansion to its lateral flow (rapid test) manufacturing capacity via the acquisition of the Doncaster-based lateral flow manufacturing facility of Concepta plc.
The site provides an additional fully automated lateral flow manufacturing capability incorporating reel to reel spraying, lamination and automated cartridge assembly.
Under a separate agreement, Abingdon Health will provide ongoing development and manufacturing services to Concepta plc to support their continued product requirements.
This new facility, together with the company’s York-based headquarters, means Abingdon Health now has two automated manufacturing facilities in Yorkshire, UK. Both sites will be capable of supporting Abingdon Health’s customer requirements including potential COVID-19 test requirements. The capacity provided by both sites, and the ability to offer customers contingency and risk planning, means Abingdon Health is well placed to support the provision of UK-based manufacturing in a lateral flow market that is seeing continued strong growth.
Chris Yates, CEO of Abingdon Health, commented:
“We are delighted to be able to support Concepta’s exciting growth plans through the provision of ongoing development and manufacture services.
We are also pleased to have acquired Concepta’s lateral flow manufacturing site in Doncaster, Yorkshire. This acquisition strengthens our UK manufacturing capabilities, providing access to additional state-of-the-art automated lines, significantly increasing our high-throughput production capacity.”
Abingdon is a UK-based developer and manufacturer of lateral flow tests and smartphone reader solutions. Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing.
Abingdon is headquartered in York, England. Visit www.abingdonhealth.com.